News

Medscape9h
FDA Widens Indication of Finerenone for Heart Failure Patients
The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.
Clinical Advisor13h
Kerendia Approved for Patients With Heart Failure and LVEF ≥40%
The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.
InvestorsHub on MSN13h
Tempus AI shares climb after FDA approval of heart monitoring software
Tempus AI, Inc. (NASDAQ:TEM) saw its stock rise 3% on Wednesday following the announcement that the company obtained 510(k) ...
Neurology Advisor15h
Kerendia Approved for Heart Failure With Left Ventricular Ejection Fraction ≥40%
Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.
Pharmabiz20h
US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%
US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...